

Attorney Docket No.: FREE.P-001-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Andrade et al.

Serial No.:

10/616,682

Filed:

07/09/2003

Confirmation:

2574

Title:

Regulation of Human Pluripotential Cells by Bone Morphogenetic

Protein 2 Antagonists

SUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicant requests that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith. No fee is believed to be due with this paper as we have not received an action on the merits. However, the Commissioner is authorized to charge any additional fees which might be due to Deposit Account No. 15-0610.

> Respectfully submitted, OPPEDAHL & LARSON LLP

Maura Idason

Marina T. Larson, Ph.D.

Reg. No. 32,038

P.O. Box 5068

Dillon, CO 80435-5068

Ph.: 970-468-6600 Fax: 970-468-0104

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this paper and the attachments mentioned herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Anne Wagner

Date of Signature (

PTO/SB/08A (06-03) Approved for use through 07/31/2003. OMB 0651-0031

the Paperwork Reduction Act of 1995, no persons are required to	U.S. Patent and Trade espond to a collection of information	mark Office; U.S. DEPARTMENT OF COMMERCE ation unless it displays a valid OMB control number
stitute for form 1449A/PTO		Complete if Known
	Application Number	10/616,682
INFORMATION DISCLOSURE	Filing Date	7/9/2003
STATEMENT BY APPLICANT	First Named Inventor	Andrade et al.
CITTI ENLETT DI TATI LICATI	Art Unit	1632

(use as many sheets as necessary) **Examiner Name** Sheet 2 Attorney Docket Number FREE.P-001-2 **U.S. PATENT DOCUMENTS**

	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
	No.1	Number-Kind Code ² (# known)	MM-DD-YYYY Applicant of Cited Document		Relevant Passages or Relevant Figures Appear		
		US-					
		US-					
		US-		·			
		US-					
		US-					
		US-					
		US-					
	_	US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-	-				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number*- Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
		WO 99/21415	5/6/1999	Stem Cell Sciences Pty. LTD.					
	-								
	<u> </u>								
	 	,							

Examiner Signature					Date Considered		
EN ALAINIES		 					 _

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.upsto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/616,682

Filing Date 7/9/2003

First Named Inventor Andrade et al.

Art Unit 1632

Examiner Name

FREE.P-001-2

(use as many sheets as necessary)
Sheet 2 of

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, Examiner Cite magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city Τ² Initials* No.1 and/or country where published. BREHM ET AL., Oct-4: more than just a POUerful marker of the mammalian germline?, APMIS, 1998, Page(s) 114-126, Volume 106 COUCOUVANIS ET AL., BMP signaling plays a role in visceral endoderm differentiation and cavitation in the early mouse embryo, Development, 1999, Page(s) 535-546, Volume 126 HEATH, Experimental analysis of teratocarcinoma cell multiplication and purification of embryonal carcinoma-derived growth fact, Teratocarcinomas and embryonic stem cells, 1987, Page(s) 183-206 HERSZFELD ET AL., Regulation of Human Pluripotent Stem Cell Differentiation by Bone Morphogenetic Protein-2, 1999, Poster presented at Combio 99, Gold Coast, Australia, Page(s) 1 LATZA ET AL., CD30 Antigen in Embryonal Carcinoma anc Embryogenesis and Release of the Soluble Molecule, American Journal of Pathology, 2/1/1995, Volume 146, Number 2 PERA ET AL., Cultured Stem-Cells from Human Testicular Teratomas: The Nature of Human Embryonal Carcinoma, and its comparison with Two Types of Yolk-Sac Carcinoma, International Journal of Cancer, 1987. Page(s) 334-343, Volume 40 PERA ET AL., Isolation and characterization of a multipotent clone of human embryonal carcinoma cells, Differentiation, 1989, Page(s) 10-23, Volume 42 PERA ET AL., Expression of CD30 and CD30 Ligand in Cultured Cell Lines from Human Germ-Cell Tumors, Laboratory Investigation, 1997, Page(s) 497-504, Volume 76, Number 4 PERA ET AL., Differentiation of human pluripotent teratocarcinoma stem cells induced by bone morphogenetic protein-2, Reproduction of Development, 1998, Page(s) 551-555, Volume 10 ROACH ET AL, Cultured Cell Lines from Human Teratomas: Windows into Tumour Growth and Differentiation and Early Human Development, Eur Urol, 1993; Page(s) 82-88, Volume 23 ROACH ET AL., Hepatocytic Transcription Factor Expression in HUman Embryonal Carcinoma and Yolk Sac Carcinoma Cell Lines: Expression of HNF-3a in Models of Early Endodermal Cell Differentiation, Experimental Cell Research, 1994, Page(s) 189-198, Volume 215

Examiner	Date	
Signature	Considered	
	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with flext communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.